Galapagos NV
GLPG
#4563
Rank
HK$16.44 B
Marketcap
HK$245.92
Share price
-0.57%
Change (1 day)
17.26%
Change (1 year)

Revenue for Galapagos NV (GLPG)

Revenue in 2025 (TTM): HK$2.49 Billion

According to Galapagos NV's latest financial reports the company's current revenue (TTM ) is HK$2.49 Billion. In 2024 the company made a revenue of HK$2.29 Billion an increase over the revenue in the year 2023 that were of HK$0.96 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Galapagos NV from 2015 to 2025

Annual revenue

Year Revenue Change
2025 (TTM) HK$2.49 B8.5%
2024 HK$2.29 B139.01%
2023 HK$0.96 B-76.79%
2022 HK$4.14 B-5.55%
2021 HK$4.38 B4.11%
2020 HK$4.21 B-41.71%
2019 HK$7.23 B174.3%
2018 HK$2.63 B131.44%
2017 HK$1.13 B5.24%
2016 HK$1.08 B222.16%
2015 HK$0.33 B

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
AstraZeneca
AZN
HK$452.49 B 18,056.32%๐Ÿ‡ฌ๐Ÿ‡ง UK
Johnson & Johnson
JNJ
HK$717.34 B 28,683.29%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
HK$369.96 B 14,744.74%๐Ÿ‡ซ๐Ÿ‡ท France
AbbVie
ABBV
HK$464.30 B 18,530.16%๐Ÿ‡บ๐Ÿ‡ธ USA
Fortress Biotech
FBIO
HK$0.46 B-81.48%๐Ÿ‡บ๐Ÿ‡ธ USA
Abbott Laboratories
ABT
HK$341.30 B 13,594.62%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
HK$130.59 B 5,140.08%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
GlaxoSmithKline
GSK
HK$329.69 B 13,129.14%๐Ÿ‡ฌ๐Ÿ‡ง UK
Merck
MRK
HK$500.04 B 19,964.19%๐Ÿ‡บ๐Ÿ‡ธ USA